Monte Rosa Q1 net loss $32M; cash $237M; MRT-2359 data on track for H2 2023

Monte Rosa Therapeutics, Inc.

Net loss $32M in Q1 2023 vs $23.9M in Q1 2022; R&D expenses $26.8M vs $17.9M.
Cash, equivalents, and marketable securities $237M as of March 31, 2023, down from $268.1M at Dec 31, 2022; runway into 2025.
Phase 1/2 trial of MRT-2359 in MYC-driven solid tumors on track for initial data in H2 2023.
VAV1 program expects to declare a development candidate in Q2 2023.
Appointed Jan Skvarka, Ph.D., MBA, to the Board of Directors.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Monte Rosa Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income Net loss for the first quarter of 2023 was $32 million.

Period: the quarter ended March 31, 2023
Net income: Net loss for the first quarter of 2023 was $32 million
Result: reported results

Exact text from the filing

On May 11, 2023, Monte Rosa Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Monte Rosa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-020846

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.